ESMO World Congress on Gastrointestinal Cancer | Conference

Treatment with FOLFOX plus cetuximab resulted in improved PFS vs FOLFOX alone in patients with metastatic colorectal cancer with “all-RAS” wild-type tumors.

A subgroup analysis of the phase III RECOURSE trial has shown that TAS-102 is effective at improving survival in patients with both KRAS wild-type or mutant metastatic colorectal cancer.

Two phase III trials have confirmed the benefit of regorafenib, an oral multikinase inhibitor, in patients with previously treated metastatic colorectal cancer.